Phase I Study of BAY73-4506 in Chinese Patients With Advanced, Refractory Solid Tumors

Summary

This will be an uncontrolled, open-label, non-randomized, phase I study. The primary objectives of this study are to define the pharmacokinetics (PK) and to evaluate the safety and tolerability of Regorafenib administered orally as a single agent in Chinese patients with advanced solid tumors. The secondary objectives are to evaluate tumor response of patients treated with Regorafenib.

Timeline

Start

2010-07

Primary completion

2012-11

Completion

2012-11

Drugs

Indications